Keyphrases
Freund Incomplete Adjuvant
100%
Phase I Trial
100%
MAGE-A3
100%
Epitope Peptide
100%
High-risk Melanoma
100%
Immune Response
57%
PADRE
57%
Vaccination
42%
T Cells
14%
Peptide Vaccine
14%
Virus Infection
14%
Epitope
14%
Protein Extract
14%
Cell Surface
14%
Tolerability
14%
Skin Test
14%
High Risk
14%
Interferon-γ
14%
Human Tumors
14%
Restimulation
14%
Effector Cells
14%
Tenderness
14%
Increased Dose
14%
Peripheral Blood Mononuclear Cells
14%
Peptide Fragments
14%
Anergy
14%
T Helper Cells
14%
Protein Antigen
14%
Local Pain
14%
HLA Molecules
14%
Phytohemagglutinin
14%
Lethargy
14%
Tumor Antigen
14%
Toxicity Response
14%
Cytolysis
14%
Stage IV Melanoma
14%
Antigen-specific Immunity
14%
Stage III Melanoma
14%
Small Peptides
14%
Global Level
14%
Pre-vaccination
14%
Injection Site
14%
Melanoma Patients
14%
Cytolytic T Cells
14%
Tumor Challenge
14%
Risk for Relapse
14%
Infection Challenge
14%
Immunology and Microbiology
Freund's Adjuvant
100%
Epitope
100%
Melanoma Antigen 3
100%
Immune Response
57%
Vaccine Efficacy
57%
Vaccination Policy
42%
T Cell
14%
Antigen
14%
Mouse
14%
Peptide Vaccine
14%
Viral Disease
14%
Cell Surface
14%
Interferon Gamma
14%
Target Cell
14%
Effector Cell
14%
T Helper Cell
14%
Peripheral Blood Mononuclear Cell
14%
Cytolysis
14%
Adaptive Immune System
14%
Phytohaemagglutinin
14%
Tumor Antigen
14%